Ranbaxy Plans Local Buyouts (India)
This article was originally published in PharmAsia News
Executive SummaryRanbaxy Laboratories plans to buy companies in India, a market that is expected to rank among the world's biggest in the next eight years. "We would certainly acquire a couple" of drugmakers, Malvinder Singh, chief executive officer of the Gurgaon-based company, said in an interview at the World Economic Forum in Dalian, China. The Indian market is expected to see "a good amount of consolidation" in the next five years, he said. India's patent laws were tightened in January 2005 to recognize product patents and stop the copying of medicines patented after 1995 by using a different manufacturing process. That may hurt drugmakers which aren't engaging in new drug research or those that don't have a strong generics business overseas, making them acquisition targets. "Small and mid-sized companies will find it tougher to survive in this environment," said Sarabjit Kour Nangra, an analyst with Angel Broking in Mumbai. "New product introductions are going to come down, which will cap their growth." (Click here for more
You may also be interested in...
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
A new coronavirus test template developed by the US Centers for Disease Control and Prevention is being refined by the agency so it can be shared with domestic and international partners to help identify more cases of the virus. In the meantime, state labs can use the posted assay for coronavirus on the CDC’s website for testing of residents within their jurisdiction and send results to the CDC.
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.